The stock price of Fennec Pharmaceuticals Inc (NASDAQ: FENC) has surged by 3.04% when compared to previous closing price of $8.54, but the company has seen a 6.28% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-03 that RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 3, 2025.
Is It Worth Investing in Fennec Pharmaceuticals Inc (NASDAQ: FENC) Right Now?
Moreover, the 36-month beta value for FENC is 0.40. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy”, 2 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for FENC is 23.03M and currently, short sellers hold a 5.93% of that float. On July 04, 2025, FENC’s average trading volume was 86.78K shares.
FENC’s Market Performance
FENC stock saw an increase of 6.28% in the past week, with a monthly gain of 11.75% and a quarterly increase of 48.15%. The volatility ratio for the week is 4.21%, and the volatility levels for the last 30 days are 5.70% for Fennec Pharmaceuticals Inc (FENC). The simple moving average for the past 20 days is 7.16% for FENC’s stock, with a 44.34% simple moving average for the past 200 days.
Analysts’ Opinion of FENC
Many brokerage firms have already submitted their reports for FENC stocks, with Cantor Fitzgerald repeating the rating for FENC by listing it as a “Overweight”. The predicted price for FENC in the upcoming period, according to Cantor Fitzgerald is $12 based on the research report published on November 22, 2022 of the previous year 2022.
CapitalOne, on the other hand, stated in their research note that they expect to see FENC reach a price target of $11. The rating they have provided for FENC stocks is “Overweight” according to the report published on September 07th, 2022.
Cantor Fitzgerald gave a rating of “Overweight” to FENC, setting the target price at $18 in the report published on June 05th of the previous year.
FENC Trading at 18.67% from the 50-Day Moving Average
After a stumble in the market that brought FENC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.92% of gains for the given period.
Volatility was left at 5.70%, however, over the last 30 days, the volatility rate increased by 4.21%, as shares surge +14.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.76% upper at present.
During the last 5 trading sessions, FENC rose by +6.28%, which changed the moving average for the period of 200-days by +60.88% in comparison to the 20-day moving average, which settled at $8.21. In addition, Fennec Pharmaceuticals Inc saw 40.35% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Raykov Rosty, the Director of Fennec Pharmaceuticals Inc, sale 10,000 shares at $7.78 during a trade that took place back on Jun 05 ’25, which means that Raykov Rosty is holding 65,462 shares at $77,800 based on the most recent closing price.
Stock Fundamentals for FENC
Current profitability levels for the company are sitting at:
- -0.39% for the present operating margin
- 0.9% for the gross margin
The net margin for Fennec Pharmaceuticals Inc stands at -0.46%. The total capital return value is set at -0.32%.
Currently, EBITDA for the company is 3.6 million with net debt to EBITDA at 2.08. When we switch over and look at the enterprise to sales, we see a ratio of 7.13. The receivables turnover for the company is 1.71for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.13.
Conclusion
To wrap up, the performance of Fennec Pharmaceuticals Inc (FENC) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
